An Single-arm Open-label Phase II Study of Decitabine Plus Penpulimab as Second-line Therapy for Advanced Esophageal Squamous Cell Carcinoma Treated With PD-1 Blockade
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Decitabine (Primary) ; Penpulimab (Primary)
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 10 Mar 2022 New trial record